Norepinephrine (bitartrate monohydrate)

Norepinephrine (Levarterenol; L-Noradrenaline) bitartrate monohydrate is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α₁, α₂, β₁ receptors^[1][2][3][4]. In Vitro:Norepinephrine (Levarterenol; L-Noradrenaline) bitartrate monohydrate is generally considered to be a β₁-subtype selective adrenergic agonist over β₂-adrenoceptor. Norepinephrine(NE) bitartrate monohydrate also has direct activity at the β₂-adrenoceptor in higher concentrations^[2].
Adipocytes from the inguinal fat pad (iWA) or the interscapular fat pad (BA) are isolated from neonatal wild-type C57BL/6J mice and cultured. To examine the effect of activating AT2 upon β-adrenergic signaling, cAMP production is first assessed in response to Norepinephrine (NE, 10 μM) with or without CGP (10 nM) co-treatment.
Norepinephrine (NE) increases cAMP as expected in iWA, and CGP does not alter this effect
Norepinephrine (NE) is also known to induce lipolysis, and liberated fatty acids are required to functionally activate UCP1 protein and to stimulate heat production. CREB phosphorylation at Ser133 is increased after Norepinephrine (NE) treatment and significantly attenuated with CGP co-treatment in mouse iWA^[3]. In Vivo:Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.